Specify a stock or a cryptocurrency in the search bar to get a summary
Oxurion NV
OXUROxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium. Address: Gaston Geenslaan 1, Leuven, Belgium, 3001
Analytics
WallStreet Target Price
0.28 EURP/E ratio
0.0031Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OXUR
Dividend Analytics OXUR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OXUR
Stock Valuation OXUR
Financials OXUR
Results | 2019 | Dynamics |